Delgocitinib has emerged as a promising treatment for CHE, addressing unmet needs and enhancing understanding of this complex condition, notes Raj Chovatiya, MD, PhD, MSCI.
Raj Chovatiya, MD, PhD, MSCI, explains how addressing the most burdensome components of chronic hand eczema can improve ...
For the primary endpoint, Eczema Area and Severity Index (EASI) improved by 53-61% in a dose-dependent manner across the ...
Clinical Trials Arena on MSN
Dupixent set for ninth US approval after Phase III AFRS success
Sanofi and Regeneron’s Dupixent (dupilumab) could be set for its ninth US approval after the drug met all the primary and ...
A study has found that people with eczema are able to bathe either daily or weekly, without any impact on their symptoms.
Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback